NanoAntibiotics to begin trading on OTC Markets

NanoAntibiotics president and director Rajah Menon noted that the company is excited to be making its debut in the public marketplace and committed to providing its investors with access to information on the company.

"We are constantly advancing towards our goal of creating the world’s ultimate weapon against bacteria, the first drug that will solve the bacterial efflux issue. Progress is continuing in the development of our platform that will selectively target and block the efflux pump in variant antibiotic resistant bacteria," Menon added.

NanoAntibiotics scientific advisor Dr Harold Landa noted that the development of multi-drug resistant efflux pumps are a major contributor to today’s growing epidemic of antibiotic resistance in both Gram-negative and Gram-positive bacteria.

"Bacteria use multiple defenses to render antibiotics harmless, including efflux pumps, which transport drugs that actually penetrate the cell back outside of cell walls to protect their nucleus. Utilizing nano-technologies to inhibit efflux pump activity so antibiotics can quickly destroy bacteria has the potential to revitalize the efficacy of many current antibiotics as well as chart a course for new drug discoveries," Dr Landa added.